| 4.08 -0.13 (-3.09%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.53  |
1-year : | 7.7 |
| Resists | First : | 5.59 |
Second : | 6.59 |
| Pivot price | 4.88 |
|||
| Supports | First : | 3.96 |
Second : | 3.29 |
| MAs | MA(5) : | 4.36 |
MA(20) : | 5.08 |
| MA(100) : | 5.77 |
MA(250) : | 4.04  |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 3.6 |
D(3) : | 3.2 |
| RSI | RSI(14): 23.1 |
|||
| 52-week | High : | 7.44 | Low : | 1.69 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AUTL ] has closed above bottom band by 4.5%. Bollinger Bands are 3.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.29 - 4.33 | 4.33 - 4.35 |
| Low: | 3.89 - 3.93 | 3.93 - 3.95 |
| Close: | 4.03 - 4.09 | 4.09 - 4.13 |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Thu, 25 Apr 2024
Recent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still ... - Yahoo Finance
Wed, 24 Apr 2024
AUTL Makes Notable Cross Below Critical Moving Average - Nasdaq
Fri, 19 Apr 2024
Autolus Therapeutics (NASDAQ:AUTL) Shares Down 5.2% - MarketBeat
Fri, 19 Apr 2024
RSI Alert: Autolus Therapeutics (AUTL) Now Oversold - Nasdaq
Fri, 19 Apr 2024
Recent 9.9% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still ... - Simply Wall St
Mon, 01 Apr 2024
Autolus Therapeutics appoints new Chairman and Director By Investing.com - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 266 (M) |
| Held by Insiders | 9.118e+007 (%) |
| Held by Institutions | 18 (%) |
| Shares Short | 2,770 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.6896e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -10 % |
| Return on Assets (ttm) | 337.3 % |
| Return on Equity (ttm) | -25.4 % |
| Qtrly Rev. Growth | 1.7e+006 % |
| Gross Profit (p.s.) | -51.82 |
| Sales Per Share | -52.65 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -146 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.08 |
| Price to Cash Flow | 12.3 |
| Dividend | 0 |
| Forward Dividend | 4.17e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|